Company Announcements

Holding(s) in Company

Source: RNS
RNS Number : 9394U
Haleon PLC
04 August 2022
 

4 August 2022

Haleon plc

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00BMX86B70

Issuer Name

Haleon plc

UK or Non-UK Issuer

UK

2. Reason for Notification

Other

Comments

Change of nominee shareholder from Wealth Nominees Limited to N.Y. Nominees Limited. See section 11 (additional information).

3. Details of person subject to the notification obligation

Name

Pfizer Inc.

City of registered office (if applicable)

New York

Country of registered office (if applicable)

United States of America

4. Details of the shareholder

Name

City of registered office

Country of registered office

Guaranty Nominees Limited

Bournemouth, United Kingdom

United Kingdom

N.Y. Nominees Limited

London, United Kingdom

United Kingdom

5. Date on which the threshold was crossed or reached

03-Aug-2022

6. Date on which Issuer notified

03-Aug-2022

7. Total positions of person(s) subject to the notification obligation


% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

32.000000

0.000000

32.000000

2955063626

Position of previous notification (if applicable)

32.000000

0.000000

32.000000


8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares 

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

GB00BMX86B70


2364050902


25.600000

Restricted ADRs


591012724


6.400000

Sub Total 8.A

2955063626

32.000000%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

 





Sub Total 8.B1




8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

 






Sub Total 8.B2




9. Information in relation to the person subject to the notification obligation

1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

 





10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

In relation to section 2 (reason for the notification), this notification is for information purposes only in relation to the transfer of Pfizer Inc. ("Pfizer")'s 2,364,050,902 ordinary shares in the capital of Haleon plc ("Haleon"), which were initially held by Wealth Nominees Limited as nominee holding on behalf of Pfizer, to N.Y. Nominees Limited as nominee holding on behalf of Pfizer. This transfer completed on 3 August 2022. Since our last notification on 18 July 2022, there have been no change to the number of voting rights in Haleon held by Pfizer, and Pfizer has not crossed any shareholding thresholds.

12. Date of Completion

03-Aug-2022

13. Place Of Completion

New York, USA

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLUSOKRUOUWRRR